PL3455631T3 - Sposoby klasyfikowania pacjentów z nowotworem litym - Google Patents

Sposoby klasyfikowania pacjentów z nowotworem litym

Info

Publication number
PL3455631T3
PL3455631T3 PL17725195T PL17725195T PL3455631T3 PL 3455631 T3 PL3455631 T3 PL 3455631T3 PL 17725195 T PL17725195 T PL 17725195T PL 17725195 T PL17725195 T PL 17725195T PL 3455631 T3 PL3455631 T3 PL 3455631T3
Authority
PL
Poland
Prior art keywords
classification
patients
methods
solid cancer
cancer
Prior art date
Application number
PL17725195T
Other languages
English (en)
Inventor
Jérôme GALON
Bernhard Mlecnik
Franck Pages
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Sorbonne Universite
Université de Paris
Assistance Publique - Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Sorbonne Universite, Université de Paris, Assistance Publique - Hôpitaux De Paris filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of PL3455631T3 publication Critical patent/PL3455631T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6862—Ligase chain reaction [LCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL17725195T 2016-05-09 2017-05-09 Sposoby klasyfikowania pacjentów z nowotworem litym PL3455631T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305536 2016-05-09
EP17725195.6A EP3455631B1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer
PCT/EP2017/061089 WO2017194556A1 (en) 2016-05-09 2017-05-09 Methods for classifying patients with a solid cancer

Publications (1)

Publication Number Publication Date
PL3455631T3 true PL3455631T3 (pl) 2021-04-06

Family

ID=56014938

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17725195T PL3455631T3 (pl) 2016-05-09 2017-05-09 Sposoby klasyfikowania pacjentów z nowotworem litym

Country Status (13)

Country Link
US (1) US20190309369A1 (pl)
EP (1) EP3455631B1 (pl)
JP (3) JP7281903B2 (pl)
KR (1) KR102245021B1 (pl)
CN (2) CN109690314B (pl)
AU (1) AU2017261685B2 (pl)
ES (1) ES2808004T3 (pl)
MX (1) MX393482B (pl)
PL (1) PL3455631T3 (pl)
RU (1) RU2745730C2 (pl)
SG (1) SG11201809317VA (pl)
WO (1) WO2017194556A1 (pl)
ZA (1) ZA201807020B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111033631B (zh) 2017-06-13 2024-03-12 波士顿基因公司 用于生成分子功能谱、对其进行可视化和分类的系统和方法
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
WO2019149817A1 (en) 2018-01-31 2019-08-08 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
FR3079617B1 (fr) 2018-03-29 2023-12-22 Office National Detude Et De Rech Aerospatiales Onera Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique
CN114072676B (zh) * 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CN110988324B (zh) * 2019-11-29 2021-08-24 广州市雷德医学检验实验室有限公司 免疫状态确定系统、方法、装置及存储介质
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
JP7741831B2 (ja) * 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法
CN113174439B (zh) * 2021-03-30 2022-06-28 中国医学科学院肿瘤医院 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用
WO2022229136A1 (en) * 2021-04-27 2022-11-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection
AU2022272594C1 (en) * 2021-05-13 2026-06-18 CentricsBio, Inc. Anti-CD300c monoclonal antibody and biomarker thereof for preventing or treating cancer
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
US20250306024A1 (en) * 2022-06-03 2025-10-02 Universita' Degli Studi Di Roma "La Sapienza" Method for determining the prognostic score in patients with metastatic renal carcinoma
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
CN115747331B (zh) * 2022-09-22 2023-08-25 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用
TWI826081B (zh) * 2022-10-28 2023-12-11 臺北醫學大學 癌症進展評估方法及其系統
CN117476097B (zh) * 2023-10-25 2024-06-07 中山大学附属第六医院 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用
CN117538532A (zh) * 2023-11-15 2024-02-09 福州汉佰康生物科技有限公司 磁微粒化学发光免疫法检测肺癌抗原浓度的试剂盒及检测方法
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119291200A (zh) * 2024-10-16 2025-01-10 华中科技大学同济医学院附属协和医院 一种用于检测cxcr4+cd8+t细胞用于预测肿瘤免疫治疗的检测试剂盒
CN120294340B (zh) * 2025-04-16 2026-06-02 青岛山大齐鲁医院(山东大学齐鲁医院(青岛)) 一种预测肝外胆管癌预后的生物标志物及其应用
CN120259410B (zh) * 2025-06-05 2025-09-23 北京大橡科技有限公司 基于双Panel多重生物标志物分析的肿瘤免疫响应可能性的评分方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050111752A (ko) * 2003-03-07 2005-11-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항신생물제에 의한 치료에 대한 종양의 감수성을 결정하는방법
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
ES2816625T3 (es) * 2010-09-24 2021-04-05 Niels Grabe Medios y métodos para la predicción de la respuesta a un tratamiento de un paciente con cáncer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
JP5970560B2 (ja) 2012-01-20 2016-08-17 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル B細胞の密度に基づいて、固形癌に苦しむ患者の生存時間を予測するための方法
ES2902879T3 (es) 2012-06-14 2022-03-30 Inst Nat Sante Rech Med Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones
JP6923291B2 (ja) 2012-07-12 2021-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも7個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
LT2880180T (lt) 2012-08-06 2019-01-25 Institut National De La Santé Et De La Recherche Médicale (Inserm) Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai
CA2900969A1 (en) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
US9851357B2 (en) 2013-07-15 2017-12-26 Inserm (Institute National De La Sante Et De La Recherche Medicale Method for the prognosis of survival time of a patient suffering from a solid cancer

Also Published As

Publication number Publication date
SG11201809317VA (en) 2018-11-29
CN109690314B (zh) 2022-08-02
EP3455631B1 (en) 2020-06-24
MX393482B (es) 2025-03-24
RU2745730C2 (ru) 2021-03-31
EP3455631A1 (en) 2019-03-20
US20190309369A1 (en) 2019-10-10
BR112018072993A8 (pt) 2022-11-22
RU2018143409A (ru) 2020-06-10
CN109690314A (zh) 2019-04-26
CN115198018A (zh) 2022-10-18
ZA201807020B (en) 2020-05-27
MX2018013744A (es) 2019-08-16
JP7654318B2 (ja) 2025-04-01
JP2022027788A (ja) 2022-02-14
WO2017194556A1 (en) 2017-11-16
JP2024019551A (ja) 2024-02-09
JP7281903B2 (ja) 2023-05-26
BR112018072993A2 (pt) 2019-03-06
KR102245021B1 (ko) 2021-04-26
KR20190016025A (ko) 2019-02-15
JP2019516979A (ja) 2019-06-20
AU2017261685B2 (en) 2023-09-07
RU2018143409A3 (pl) 2020-06-29
ES2808004T3 (es) 2021-02-25
AU2017261685A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
IL296080B1 (en) Method for treating cancer
IL255261A0 (en) Methods for treating cancer
IL258955A (en) Compositions and methods for treatment of cancer
EP3402517A4 (en) Immunologic treatment of cancer
IL253162A0 (en) Compositions and methods for treatment and detection of cancers
IL261422A (en) Therapeutic and diagnostic methods for cancer
IL255312A0 (en) Therapeutic and diagnostic methods for cancer
IL251890A0 (en) Combination immunotherapy approach for treatment of cancer
IL252361A0 (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
PL3283527T3 (pl) Leczenie skojarzone nowotworów
GB201616912D0 (en) Classification of cancer
HUE059694T2 (hu) Készítmény rák kezelésére
IL262208A (en) Diagnostic and therapeutic methods for cancer
IL263802A (en) Cancer treatment combinations
HUE038541T2 (hu) Rák kezelési módszerek
PL3198009T3 (pl) Onkolityczne wirusy nowotworowe i sposoby zastosowania
IL253160B (en) Cancer markers and methods of use thereof
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
HUE054673T2 (hu) Rák kezelésére szolgáló eljárások és készítmények
PL3525774T3 (pl) Leczenie lazofoksyfenem raka piersi er+
PT3622953T (pt) Tratamento combinado do cancro
EP3413927A4 (en) CANCER THERAPY
EP3593139C0 (en) CANCER BIOMARKERS
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
PT3134119T (pt) Tratamento do cancro